COVER SHEET FOR DOCUMENT TRANSMISSION

File: 970107_sep96_decls61_0007.txt
Page: 0007
Total Pages: 7

Subject: COVER SHEET FOR DOCUMENT TRANSMISSION                           

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003205

Folder Title: 4TH USAMRDC LEISHMANIASIS VARIOUS LEVELS                                                        

Document Number:          1

Folder Seq  #:         12



                       The cc-nany has indicated that larne quantities of
                    vaccine c4L d be made available if ne id. This vaccine
                    would be available in approximately 4 months. Availability
                    of research lots is being ascertained.

                    3. WRAIR Research Plans

                         Plans have been developed to evaluate this vaccine at
                    Schofield Barracks. Evaluation of a 0, 6 and 0, 12 month
                    schedule using both the 200 and 400 ng products have been
                    planned. With blood specimens being drawn shortly after
                    the initial dose, data on the immune response to one dose
                    would be available. In addition, short immunization
                    schedules have been formulated. (0, 14 days, 0, 30 days,
                    and a double dose at time 0). Data from these studies
                    would be available by the end of March.

                    4. Recommendation for use of MSD vaccine

                      a. Defer fielding of this vaccine until at least 500
                      successful, safe immunizations have been completed.



                C.  WRAIR's vaccine

                    1. Status of development

                         An IND exemption is in place. Further studies of the
                    crude prototype were carried out at Ft. Lewis. The vaccine
                    was 90% immunogenic, regardless of whether 3 or 4 doses
                    were used. A decision was made to proceed with development
                    of a more highly purified vaccine.
                         The Salk Institute is producing the WPAIR vaccine.
                    our large scale production method for a highly purified
                    vaccine is still being developed.

                    2. Availability

                         This vaccine is unavailable for large scale use at
                    this time.




                  CHARLES H. HOKE, JR
                                        COL, MC
                                        Chairman
                                        USAKRDC Hepatitis Steering Committee*













                                              6

Document 7 f:/Week-36/BX003205/4TH USAMRDC LEISHMANIASIS VARIOUS LEVELS/cover sheet for document transmission:01029715474762
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003205
Unit = OTSG
Parent Organization = HSC
Folder Title = 4TH USAMRDC LEISHMANIASIS VARIOUS LEVELS
Folder Seq # = 12
Subject = COVER SHEET FOR DOCUMENT TRANSMISSION
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 02-JAN-1997